| 摘要: |
| 二甲氨基菊酯（DMAMCL，即ACT001）是一种通过含笑内酯（michelioide，MCL）的二甲氨基Michael加成反应合成的化疗药物，具有较好的缓释作用和较高的口服生物利用度。研究表明，DMAMCL具有抗肿瘤、神经保护与抗炎等多种生物药理学活性，具有重要的临床应用价值。本文综述了DMAMCL的药理学作用，为其进一步开发利用提供科学依据。 |
| 关键词: 二甲氨基菊酯 药理作用 研究进展 |
| DOI：10.11724/jdmu.2021.01.12 |
| 分类号:R96 |
| 基金项目:国家自然科学基金项目（81872156；81673762） |
|
| Research progress on pharmacological action of DMAMCL |
|
MA Jing1, ZHAO Zuowei2, LI Man1
|
|
1.Department of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China;2.Department of Breast Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China
|
| Abstract: |
| Dimethylaminomicheliolide (DMAMCL, i.e., ACT001) is a chemotherapeutic drug synthesized by dimethylamino Michael addition reaction of micheliolide (MCL), and it has good sustained release effect and high oral bioavailability. Studies have shown that DMAMCL has a variety of bio-pharmacological activities, including anti-tumor, neuroprotection and anti-inflammation. Therefore, DMAMCL has great clinical application value. This paper reviews the pharmacological action of DMAMCL, aiming to provide scientific basis for its further development and utilization. |
| Key words: DMAMCL pharmacological action research progress |
